Sotera Health Company

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.

Are you a current or former employee of the company?*YesNo

Purchases

+Additional Purchases

Sales

+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:




There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com

Sotera Health Company’s EtO processing emitted toxins and caused cancer in people living near its sterilization facilities in several states. Lawsuits were filed by cancer-stricken plaintiffs, and the company denied the allegations. Sotera conducted an initial public offering (IPO) in November 2020 and a secondary public offering (SPO) in March 2021. However, the Offering Materials contained materially false and misleading information about the company’s emissions control systems and exposure to liability. In September 2022, an Illinois state court found Sotera liable for a plaintiff’s cancer and awarded $363 million in damages. The disclosure caused the company’s stock price to decline by over 68% below the IPO price and nearly 73% below the SPO price.